UPDATE 1-Glaxo cuts Cervarix price by 30 pct in Canada


LONDON | Mon Oct 25, 2010 6:34am EDT

LONDON Oct 25 (Reuters) – GlaxoSmithKline (GSK.L) has cut the price of its cervical cancer vaccine Cervarix by 30 percent in Canada in a bid to encourage greater uptake of the product.

Recent research has identified the relatively high price of cervical cancer vaccines and low understanding of their benefits as key reasons why most young Canadian women have yet to be immunised, the British drugmaker said on Monday.

The new list price for Cervarix is C$90 ($87.63) per dose, down from C$134.95 previously. Three doses of the vaccine are recommended for protection.

Both Cervarix and Merck & Co’s (MRK.N) rival vaccine Gardasil protect against infection with the sexually transmitted human papillomavirus, which can cause cervical cancer. (Reporting by Ben Hirschler, editing by Kate Kelland)

Somebody is not buying something….
Never doubt what a small group of committed people can do in exposing the truth about the HPV vaccines.


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.